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ABSTRACT: Carbamazepine has been found to crystallize as a new polymorph that is
stable at room temperature. We report the crystal structure of this C-centered
monoclinic form (space group C2/c, cell parameters: a¼ 26.609, b¼ 6.9269, c¼ 13.957,
b¼ 109.702), which consists of hydrogen bonded dimers with an anti-disposition. This
represents the third modification of carbamazepine that has been crystallographically
characterized, and the fourth for which cell parameters have been determined. Thus, it
is designated as form IV of carbamazepine. Differences between the packing of the
various polymorphs are discussed.  2002 Wiley-Liss, Inc. and the American Pharmaceutical
Association J Pharm Sci 91:1186–1190, 2002
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INTRODUCTION
Carbamazepine is an important drug for the
treatment of epilepsy and trigeminal neuralgia
whose crystallization has been thoroughly docu-
mented in nearly 100 publications in the litera-
ture with three stable forms being extensively
characterized.1–14 Furthermore, because its bio-
availability has been demonstrated to depend on
the polymorph administered, its polymorphism is
of great practical importance.7 The most stable of
the known polymorphs at room temperature is a
monoclinic form (form III) in the space group P21/
c with lattice parameters a¼ 7.529, b¼ 11.148,
c¼ 15.470, b¼ 116.17.2 The molecules pack as
hydrogen bonded dimers through the carbox-
amide group with an anti (centrosymmetric)
relationship. The trigonal form (form II) has also
been analyzed by single crystal X-ray diffraction
and crystallizes in the space group R3 with
a¼ 35.454, c¼ 5.253.4 Although the molecules
exist as dimers very similar to the monoclinic
form, the packing of these units around a three-
fold screw axis leads to a more open structure
(density at room temperature is 1.235 g/cm3 and
1.343 g/cm3 for the trigonal and monoclinic1
forms, respectively). A triclinic polymorph (form
I) has been characterized by powder X-ray
diffraction. Indexing of the powder pattern is
consistent with the following lattice parameters:
a¼ 20.61, b¼ 5.24, c¼ 22.30, a¼ 89.4, b¼ 84.5,
g¼ 85.5.3 Assuming eight molecules in the unit
cell gives a calculated density at room tempera-
ture of 1.31 g/cm3. The relationships among these
three forms have been studied in detail, and it is
observed that upon melting the monoclinic form
converts to the triclinic.15
During our studies on the crystallization of
carbamazepine we found that evaporation of
0.3 mL of a methanol solution (1.5 g/100 mL,
208C) of the compound in the presence of 12 mg of
hydroxypropylcellulose (Mw¼ 60,000, Scientific
Polymer Products, Inc., Ontario, NY) led to the
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formation of plate-like crystals in some trials in
addition to the known triclinic (needles) and
monoclinic (prisms) crystals. Production of this
form by seeding supersaturated methanol solu-
tions (1.5 g/10 mL, 208C) yielded crystals as
aggregates of plates occasionally contaminated
with small amounts of triclinic needles (Figure 1).
Elemental analysis agreed well with pure carba-
mazepine (Anal. calcd for C15H12N2O: C, 76.25; H,
5.12; N, 11.86%. Found C, 76.10; H, 5.17; N,
11.81%), and this data combined with the lack of
mass loss in the TGA ruled out a solvate. To
elucidate the arrangement of the molecules in this
new polymorph we performed single crystal X-ray
diffraction.
Collection of a full data set confirmed that, even
in the case of this very well studied pharmaceu-
tical, a new polymorph had been obtained.16
Carbamazepine was induced to crystallize in a
C-centered monoclinic cell in the space group C2/
c. Cell parameters are a¼ 26.609, b¼ 6.9269,
c¼ 13.957, b¼ 109.702, and the density is
1.296 g/cm3 (158 K, 1.268 g/cm3 using unit cell
data acquired at 298 K) making this polymorph
easily distinguishable from the known monoclinic
form, which crystallizes in a primitive cell.17 The
bond lengths do not differ significantly from those
determined for the primitive monoclinic or trigo-
nal polymorphs (Figure 2, Tables 1 and 2). The
azepine ring adopts a boat conformation similar to
that found in the other structurally characterized
forms, and the angles differ only slightly between
the two monoclinic forms. Large differences
among the torsional angles of the carboxamide
group are not observed between the three forms,
perhaps a result of the dominance of dimer form-
ation in dictating geometry.
The molecules pack as hydrogen-bonded
dimers through the carboxamide group with an
anti relationship (Figure 3). Although the con-
formation of the molecules within the dimers is
similar among all three polymorphs, substantial
differences exist between the packing of these
units. The oxygen of the new polymorph is
engaged in two short intermolecular hydrogen
Figure 1. Observed morphology of the new carba-
mazepine polymorph obtained by seeding of a super-
saturated solution.
Figure 2. Thermal ellipsoid diagram of the C-cen-
tered monoclinic polymorph of carbamazepine.
Table 1. Atomic Coordinates ( 104) and Equivalent
Isotropic Displacement Parameters (A2 103) for C-
Centered Monoclinic Carbamazepine
x y z U(eq)a
O(1) 722(1) 55(1) 366(1) 33(1)
N(1) 145(1) 1802(2) 841(1) 42(1)
N(2) 1059(1) 2309(2) 372(1) 29(1)
C(1) 640(1) 1278(2) 257(1) 28(1)
C(2) 1596(1) 1662(2) 140(1) 28(1)
C(3) 1841(1) 2041(2) 1168(1) 33(1)
C(4) 2349(1) 1364(2) 1674(1) 38(1)
C(5) 2615(1) 297(2) 1155(1) 38(1)
C(6) 2376(1) 48(2) 129(1) 36(1)
C(7) 1862(1) 632(2) 409(1) 31(1)
C(8) 1633(1) 269(2) 1503(1) 38(1)
C(9) 1284(1) 1351(2) 2218(1) 39(1)
C(10) 1054(1) 3185(2) 2078(1) 33(1)
C(11) 917(1) 4560(2) 2865(1) 42(1)
C(12) 731(1) 6360(2) 2746(1) 45(1)
C(13) 674(1) 6870(2) 1828(1) 44(1)
C(14) 800(1) 5551(2) 1039(1) 36(1)
C(15) 976(1) 3720(2) 1166(1) 30(1)
aU(eq) is defined as one-third of the trace of the orthogo-
nalized Uij tensor.
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Table 2. Bond Lengths [Å] and Angles [8] for C-Centered Monoclinic Carbamazepine
O(1)–C(1) 1.2362(14) C(1)–N(2)–C(2) 119.27(10)
N(1)–C(1) 1.3446(16) C(1)–N(2)–C(15) 121.52(10)
N(2)–C(1) 1.3772(15) C(2)–N(2)–C(15) 117.54(9)
N(2)–C(2) 1.4374(15) O(1)–C(1)–N(1) 122.16(11)
N(2)–C(15) 1.4382(15) O(1)–C(1)–N(2) 120.77(11)
C(2)–C(3) 1.3866(18) N(1)–C(1)–N(2) 117.07(11)
C(2)–C(7) 1.3999(17) C(3)–C(2)–C(7) 121.01(12)
C(3)–C(4) 1.3791(19) C(3)–C(2)–N(2) 119.73(11)
C(4)–C(5) 1.385(2) C(7)–C(2)–N(2) 119.26(11)
C(5)–C(6) 1.378(2) C(4)–C(3)–C(2) 120.21(13)
C(6)–C(7) 1.4010(19) C(3)–C(4)–C(5) 119.90(13)
C(7)–C(8) 1.4626(19) C(6)–C(5)–C(4) 119.90(13)
C(8)–C(9) 1.340(2) C(5)–C(6)–C(7) 121.55(13)
C(9)–C(10) 1.450(2) C(2)–C(7)–C(6) 117.40(12)
C(10)–C(11) 1.4066(19) C(2)–C(7)–C(8) 123.29(12)
C(10)–C(15) 1.4067(17) C(6)–C(7)–C(8) 119.30(12)
C(11)–C(12) 1.372(2) C(9)–C(8)–C(7) 128.42(14)
C(12)–C(13) 1.385(2) C(8)–C(9)–C(10) 127.40(13)
C(13)–C(14) 1.3826(19) C(11)–C(10)–C(15) 116.70(13)









Figure 3. Molecular packing of the C-centered monoclinic polymorph of carbamaze-
pine viewed along the b-axis revealing the presence of hydrogen-bonded dimers.
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bonds. The closest contact between the normal-
ized (1.083 Å, CH; 1.009 Å, NH) position of the
hydrogen on the urea syn to the oxygen of the
carbonyl is 1.86 Å. This distance is similar to that
in the primitive monoclinic polymorph (1.92 Å).
However, in the new polymorph the carbonyl is
only 2.28 Å from a vinylic hydrogen in the seven-
membered ring while the corresponding value
is 2.48 Å in the primitive monoclinic form. This
CHO hydrogen bond links adjacent dimer pairs
into infinite chains. The hydrogen on the urea
anti to the oxygen of the carbonyl is > 2.7 Å from
an aromatic carbon, and is similar in both mono-
clinic forms. Differences between the p–p inter-
actions are also apparent among the three
structures. The trigonal form lacks close facial
aromatic stacking with shortest centroid-to-cen-
troid distances of greater than 5 Å. By contrast,
the primitive monoclinic polymorph contains both
a long (centroid–centroid: 3.821 Å, centroid–
plane: 3.785 Å), nearly direct face-to-face stacking
of inversion-related rings and a relatively shorter,
but slightly slipped (centroid–centroid: 3.947 Å,
centroid–plane: 3.542, 3.686 Å), stacking between
inequivalent benzene rings. The C-centered
monoclinic form displays the closest stacking
between the rings composed of carbons number
2 thru 7 (centroid–centroid: 3.809 Å, centroid–
plane: 3.445 Å).
Because this is the fourth well-characterized
polymorph of carbamazepine, we designate it as
form IV.18 We are currently studying the stability
of this form at elevated temperature and humid-
ity. Future studies will include the measurement
of the dissolution rate and equilibrium solubility
to determine if this may be a more efficacious form
of this important drug.
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